AnthonySteinMD

Oncology • Duarte, CA

Physician

Join to view full profile

Dr. Stein is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Stein's full profile

Already have an account?

Office
Division of Leukemia
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3060
Is this information wrong?

Education & Training

City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1987
UPMC Medical EducationResidency, Internal Medicine, 1982 - 1984
University of Cape Town Faculty of MedicineClass of 1978

Certifications & Licensure

CA State Medical License 1984 - 2024
PA State Medical License 1983 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) Start of enrollment: 2005 Jun 01
Completed
Phase 2
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 1994 Sep 01
Completed
Phase 2
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer Start of enrollment: 2000 Feb 29
Active, not recruiting
Phase 2
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R Start of enrollment: 2000 Feb 08
Active, not recruiting
Phase 2
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer Start of enrollment: 2007 Jun 11
Terminated
Phase 1, Phase 2
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Start of enrollment: 2008 Mar 04
Active, not recruiting
Phase 1, Phase 2
Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 2007 Jul 01
Completed
Phase 1
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm Start of enrollment: 2010 Aug 01
Completed
Phase 2
Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome Start of enrollment: 2013 Jan 01
Terminated
Phase 1, Phase 2
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML Start of enrollment: 2014 May 12
Recruiting
Phase 2
SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
Completed
Phase 1, Phase 2
Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2018 Mar 19
Recruiting
Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax Start of enrollment: 2022 Jul 29
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Al Malki, M. M., Jianying Zhang, Jose Tinajero, Hoda Pourhassan, Vinod Pullarkat, Vaibhav Agrawal, Paul Koller, Ahmed Aribi, Amandeep Salhotra, Karamjeet Sandhu, Haris...> ;British Journal of Haematology. 2024 Mar 31
1 citations
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
Shai Shimony, Jan Philipp Bewersdorf, Rory M Shallis, Yiwen Liu, Eva J Schaefer, Amer M Zeidan, Aaron D Goldberg, Eytan M Stein, Guido Marcucci, R Coleman Lindsley, Ev...> ;Leukemia. 2024 Apr 1
Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
Lasky, J., Mullen, C., Angelucci, E., Vinti, L., Pemmaraju, N., Cuglievan, B., Kheradpour, A., Hijiya, N., Stein, A., Meshinchi, S., Mughal, T., Pawlowska, A.> ;Ejhaem. 2024 Feb 1
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo, D., Tinajero, J., Li, S., Palmer, J., Pourhassan, H., Aribi, A., Nakamura, R., Stein, A., Marcucci, G., Salhotra, A., Sandhu, K., Pullarkat, V., Ball, B., Koller, P.> ;Leukemia & Lymphoma. 2024 Mar 1
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplant...
Flavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, Jing Li, Minh Ly, Katelyn Faircloth, Jada Mack-Onyeike, Corinna La Rosa, Sandra Thomas, Qiao Zhou, J...> ;Vaccines. 2023 Sep 15
-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Ahmed Aribi, Amandeep Salhotra, Michelle Afkhami, Anamaria Munteanu, Haris Ali, Ibrahim Aldoss, Salman Otoukesh, Monzr M Al Malki, Karamjeet S Sandhu, Paul Koller, Shu...> ;Leukemia & Lymphoma. 2023 Aug 3
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation UsingY-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan i...
Matthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, Jennifer Simpson, James O'Hearn, Anthony Stein, Stephen Forman, Ricardo Spielberger, Ji-Lian Cai, Myo Htut, Ryotar...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
1 citations
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Ver...
Janny M Yao, Salman Otoukesh, Hanna Kim, Dongyun Yang, Sally Mokhtari, Yazeed Samara, Amanda Blackmon, Shukaib Arslan, Vaibhav Agrawal, Hoda Pourhassan, Idoroenyi Aman...> ;Transplantation and Cellular Therapy. 2023 Aug 1
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
Al Malki, M. M., Idoroenyi Amanam, Janny Yao, Alfredo Puing, Ni-Chun Tsai, Diana Samuels, Dat Ngo, Stephanie Ho, Haris Ali, Ahmed Aribi, Shukaib Arslan, Andrew Artz, M...> ;Cancer Medicine. 2023 May 1
4 citations
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Phila...
Ibrahim Aldoss, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari, Shilpa Shahani, Hoda Pourhassan, Vaibhav Agrawal, Paul Koller, Shukaib Arslan, Vanina Tomas...> ;American Journal of Hematology. 2023 Jun 1
Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
Ahmed Aribi, Amandeep Salhotra, Brian Ball, Anthony Stein, Guido Marcucci, Vinod Pullarkat> ;Leukemia & Lymphoma. 2023 Apr 1
12 citations
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
1 citations
The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
Vaibhav Agrawal, Amandeep Salhotra, Joo Song, Zhaohui Gu, Anthony S Stein, Guido Marcucci, Stephen J Forman, Vinod Pullarkat, Ibrahim Aldoss> ;American Journal of Hematology. 2023 Feb 1
1 citations
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Vaibhav Agrawal, Hoda Pourhassan, Ni-Chun Tsai, Dat Ngo, Paul Koller, Monzr M Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S Sandhu, Shukaib Arslan, ...> ;Transplantation and Cellular Therapy. 2023 May 1
2 citations
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
Corinna La Rosa, Flavia Chiuppesi, Yoonsuh Park, Qiao Zhou, Dongyun Yang, Ketevan Gendzekhadze, Minh Ly, Jing Li, Teodora Kaltcheva, Sandra Ortega Francisco, Miguel-An...> ;Frontiers in Immunology. 2023 Jan 1
2 citations
The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.
Dat Ngo, Salman Otoukesh, Anthony S Stein, Stephen Forman, Vinod Pullarkat, Ibrahim Aldoss> ;Leukemia & Lymphoma. 2022 Nov 1
3 citations
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors.
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo,...> ;Leukemia & Lymphoma. 2023 Jan 1
11 citations
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Ibrahim Aldoss, Samer K Khaled, Xiuli Wang, Joycelynne Palmer, Yan Wang, Jamie R Wagner, Mary C Clark, Jennifer Simpson, Jinny Paul, Vibhuti Vyas, Sheng-Hsuan Chien, A...> ;Clinical Cancer Research. 2023 Feb 16
3 citations
Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early F...
Colton Ladbury, Saro Armenian, Alysia Bosworth, Tianhui He, F Lennie Wong, Savita Dandapani, Chunhui Han, An Liu, Monzr Al Malki, Joseph Rosenthal, Anthony Stein, Jeff...> ;Transplantation and Cellular Therapy. 2022 Dec 1
7 citations
Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.
Ibrahim Aldoss, Dongyun Yang, Vanina Tomasian, Sally Mokhtari, Ryan Jackson, Zhaohui Gu, Milhan Telatar, Hooi Yew, Monzr M Al Malki, Amandeep Salhotra, Samer Khaled, H...> ;Blood Advances. 2022 Sep 13
3 citations
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemi...
Brian J Ball, Shukaib Arslan, Paul Koller, Dat Ngo, Michelle Afkhami, Amandeep Salhotra, Monzr Al-Malki, Ahmed Aribi, Haris Ali, Karamjeet Sandhu, Salman Otoukesh, Ido...> ;Leukemia & Lymphoma. 2022 Dec 1
6 citations
Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.
Jan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo,...> ;Leukemia Research. 2022 Nov 1
14 citations
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Naveen Pemmaraju, Kendra L Sweet, Anthony S Stein, Eunice S Wang, David A Rizzieri, Sumithira Vasu, Todd L Rosenblat, Christopher L Brooks, Nassir Habboubi, Tariq I Mu...> ;Journal of Clinical Oncology. 2022 Sep 10
4 citations
Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission.
Anthony S Stein, Monzr M Al Malki, Dongyun Yang, Joycelynne M Palmer, Ni-Chun Tsai, Ibrahim Aldoss, Haris Ali, Ahmed Aribi, Andrew Artz, Savita Dandapani, Len Farol, S...> ;Transplantation and Cellular Therapy. 2022 Jul 1
8 citations
Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research.
Sophia K Khaldoyanidi, Antreas Hindoyan, Anthony Stein, Marion Subklewe> ;Critical Reviews in Oncology/hematology. 2022 Jul 1
Join now to see all

Journal Articles

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Initial Findings of the Phase 1 Trial of PBCAR0191, a CD19 Targeted Allogeneic CAR-T Cell Therapy
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE¬ (Bispecific T-Cell Engager) in Patients with R...
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Anthony Stein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in AdultsClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Changing Game Plan for Acute Lymphocytic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Innate Pharma to Present Results from a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients with Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022November 4th, 2022
City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual ConferenceDecember 8th, 2020
Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy Than Physician Prescribed TreatmentsMay 14th, 2020
Join now to see all